KRAS and colorectal carcinoma: Studies revealed that CRC patients with wild-type KRAS and MSI could benefit from targeted chemotherapy, which might be mediated by gut bacteria and phages described above (Nakatsu et al., 2018; Kannen et al., 2019; Zheng et al., 2019; Phipps et al., 2020).